Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Fluticasone Propionate Oral Dispersible Tablet Formulation in Eosinophilic Esophagitis: A Two-Part, Randomized, Double-blind, Placebo-Controlled Study of APT-1011 With an Open-label Extension, in Adult Subjects With Eosinophilic Esophagitis

NCT04281108 is registered in ClinicalTrials.gov with Ellodi Pharmaceuticals, LP as lead sponsor.

NCT NCT04281108
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04281108 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Fluticasone Propionate Oral Dispersible Tablet Formulation in Eosinophilic Esophagitis: A Two-Part, Randomized, Double-blind, Placebo-Controlled Study of APT-1011 With an Open-label Extension, in Adult Subjects With Eosinophilic Esophagitis
Lead sponsor
Ellodi Pharmaceuticals, LP
Phase
Phase 3
Overall status
Completed
Start date
January 30, 2020
Completion date
October 24, 2022
Enrollment
143 (actual)
Sites
56

Conditions

As the registry lists them; a condition with its own page is linked.

eosinophilic esophagitis